Antibe Therapeutics Inc(Pre-Merger) ATBPF

Share price taken down

[woundedknee]

By suspicious actions. Very low trading which leads me to believe this is totally manipulated by one or two traders or brokerage houses. I would be concerned if there were hundreds of thousands or millions of shares traded daily, but this is not the case. So if you shorters or MMs want to play this game then go for it..I will buy more as you take it down. As an observation over the past several years I firmaly believe that manipulators just snub their noses at regulators, because they know most times they get away with breaking all the rules. I could say more, but I won't. gl

[123ABC]

Of course blame the boogeyman when stock is crashing

[MrMugsy]

Exactly. They take it down, we're ready with cash to buy what we believe to be cheap ... and the future winners.  That's the only game I've ever really played.

[GameChangerBet]

If you're willing to give this enough time, by that I mean 2-3 years, the only thing that's essentially going to matter is whether or not this product will ultimately get to market. With all the information I'm aware of, Phase l and phase ll results, Nuance believing as such, FDA's approval to proceed, I find it hard to find any evidence to the contrary. Phase lll will have a

[MrMugsy]

Yes Gamechanger - agree with your comments. I placed a considerable bet after the company figured out their P1 problem and as they were heading into P2 (close to 4 years ago ?) Two interesting things for P3 ... 1.  we will get to see if there is ulceration repair over a longer duration of the trial 2.  we will get to see what happens when an idependent committee gets to look at the

[RjM2018]

Has anyone ever looked at price depresseion of stocks upon announcing their application for nasdaq uplisting?  I noticed CRDL.TO is substantially down since announcing they've applied for uplisting. I haven't looked into short interest etc during these time frames, but think it would be an interesting study. I'd speculate that theres intential manipulation to decrease stock

[StockingUp21]

please explain why no buyers. Why no insider buying. Why losing analyst and lower price target. This is not the boogeyman doing this. Downward trend is normal here.   

[woundedknee]

Downward trends occur with every stock. There isn't a stock in history that has not experienced a downward trend at one time or another. All I said was that I believed this trend was not normal because of the low volume and it was just an opinion. This could also be attributed to the old saying "sell in May and go away", who knows. It's very clear to me why there are very few

[woundedknee]

I just checked Thompson Reuters and they still list 6 analysts covering the stock with a buy. gl

[WalkOverTheStrt]

Why would an instution wait for the PH3 start to buy as the co. received FDA apporval to start? Is the actual act of starting a PH3 one of the main factirs in determing taking a position? I hope not.  Antibe is a micro cap on a backwater exchange. Fall can't get here soon enough and hopefully a partner announcement to put wind in the sails...

[Arbourmark]

Can you explain what you mean by a backwater exchange, you must be an American with such a comment. Do you have any idea the market cap size of various companies listed on TSX. There is no doubt exposure to big board US listings is not going to hurt but it's quite insulting to call the TSX a backwater exchange, this is not the TSXV or CSE.  

[LosAngelesDave]

Webster defines backwater exchange - see TSX.   You have 2 biotechs over 1b cap, Tril and Aup.  Hence the backwater designation.  Synonym - see janky, minor, wannabe, #wanttobeusa

[StockingUp21]

I think everyone agree need for nasdaq.    but not option now. Market cap lower than IPO, dilute shareholder over and over. Reverse split for nasdaq, then dilute by 30% and no longer qualify.    

[GameChangerBet]

Perhaps expand your intelligence, or at least make an effort to understand what exactly is going on. The same, uninformed rhetoric. " Dilution, dilution, dilution".  This is a junior Canadian Biotech company. From zero to phase lll. Do you really not understand the necessity of those equity raises? Instead of continuing to repeat the same, useless commentary, why not provide an idea

[StockingUp21]

No point argue with cult member or pumper. Nothing wrong here. Unfortunately uneducated is all that invest here. Including me.  

[GameChangerBet]

"No point argue with cult member or pumper. Nothing wrong here. Unfortunately uneducated is all that invest here. Including me." See what I mean? After everything that was just said and explained, the response to it is a one sentence reply doing nothing but retreating to use terms like "pumper".

[StockingUp21]

you insist. Here they can reverse split for reason said, make sure to hit target stated. Like advance second drug they have been talking for many years. not selling or dilution second steam is gaining. Not selling own shares and dilute at discount following week.not waste money on subsidiary for years not waste money on IR service that dont serve exchange they are listed. I say no point in

[baggerx99]

Either a win or loss at the finish line, Otena will be a win, from all meaningful posts and mgmt knowingly have proven that Otena is GI safe,,,,period. Overall Otena can not being any worse than Naproxen by itself.

[MrMugsy]

And here's a thought to go with that Bagger ... Let's just assume that a problem develops with OTENA w.r.t the H2S. Once upon a time, that would have been - GAME OVER for NSAIDs. Not the case anymore. For there to be a problem, there would need to be an ineffiicient release of the H2S that causes a major problem.  If that were true, ATE can argue that Big Pharma's investment in

[WalkOverTheStrt]

Arbourmark, My apologies as my word choice was more of frustration of the current stagnation and unclear reason to perform a R/S and then wait half a year or more to list on a major US exchange.    The the total market capitalization of companies listed on TSX & TSXV is listed from various sources at  $2.3T to $3.2 T, not a figure to dismiss lightly, while the total value

[HarveyTwoface]

The science is solid but oh boy, our Dan is not a salesman, he needs to retire before we all have lost our money.

[MrMugsy]

I'm assuming that's just frustration talking as Dan is likely in the middle of multiple roadshows.  I don't have any details but I'd assume he's the main guy working on introductions with Big Pharma and in the discussions with Institutional Investors. I'm also guessing that the Institutional Investors and the NASDAQ will go hand-in-hand ... so ... until such a day

[HarveyTwoface]

I appreciate your very intelligent answer. Thanks for being a beacon in the board darkness.

[MrMugsy]

Thanks Harvey ... just trying to understand our potential and the potential of the drug. What did Dan say ... 20+ molecules and we are presently using 3 of them ... something like that. I think one is for the NSAIDs - one for the the IBD drug - and one was potentially for the future replacement to our NSAIDs (likely for 340 trials at this time).  Lots of others and maybe we're adding

[woundedknee]

Are any of these big pharmas even aware that Antibe exists? If so why has there not yet been any indication of colaborations (other than Nuance) at this stage in the game. For example Ventripoint (V.VPT) just recently made a colaboration agreement with GE Healthcare. Ventripoint is still a venture listed company trading at 40 cents give or take. So why the arguement (which I have supported) that

[GameChangerBet]

Nasdaq uplist is for attracting U.S institutional investors. Has nothing to do with Big Pharma. Big Pharma agreement can occur at any time. 

[MrMugsy]

But ... the NASDAQ will likely have an effect on future share price - via the institutional investor base and a larger future following. And I will bet that ATE could have made deals with Big Pharam already - but they would have been sub-optimal deals. Why only a Nuance deal and no other deals?  Simply put ... the Nuance deal was strategic from the point of raising cash and buying time

[woundedknee]

Mugsy..I guess you're right about the nuance deal. Because right now the market is giving zero value to it. jmo

[MrMugsy]

Agreed - the market is giving no value to Nuance or to the minimum value that should exist for all future partnerships (based on Nuance).  Volume on the markets has dried up and waiting for buyers to return.  Perfect time for the company to help create that future excitment.  IMO. I think the share price is elsewhere once we're into P3 and likely another boost by the time we

[MrMugsy]

Sorry Gamechanger ... should have said ... Why only the Nuance deal and no other deals?  To buy time as we go into P3 (to your point) ... and ... to prove out the IP.

[Yellowknifer69]

Hello and good morning ATE Longs: Hope all are well and staying Covid-Free.  To the point about heading into P3, I thought I read something from Dan indicating that the Company had no intention of actually starting the clinical trials.  That something would likely transpire well before that time?  Can anybody clarify? With thanks, Staying long, no place else to go - literally

[MrMugsy]

True - they don't want to take OTENA to P3 on their own. That comment came from Dan years ago - before being fully funded - and it's been echoed by the company since. I'm sure they would like to strike a deal sooner than later - or a deal in principal - or even a conditional deal ... but ... this is still very fluid and evloving (IMO only). I don't think they can promise anything

[Actuarial]

Agreed. Makeing a deal before P3 is preferred but it is never a promise nor a sure thing to happen. Negatiation doesn't alway result in a deal because of a lot of things, one of them is price. The only thing so far we have confidence is the science of H2S platform. ATE has enough cash to take 346 through P3 alone even in the worst scenario. Other scenarios can only be better. Nothing truly to

[WalkOverTheStrt]

Mugs - any indication that mgmt tries to accelerate 352  "Currently in IND-enabling studies — human trials slated for 2022"?  It just seems like a very open date and having watched Dan and team push timelines out Im curious if with the funding they will try to make up for lost time. IMO and I'm a broken record until Antibe has more than one human drug results (positive

[MrMugsy]

No I don't think he's indicated that re. 352 timelines. I have asked question about fast-track ... as I know there is a definate value for fast-track but only to an acquirer of 352 or an acquirer of the company.  So good to get there sooner than later.  Just don't know the plan. Sorry ... not much help.

[StockingUp21]

Not even CeO knows what is going on with this company. No matter what I voting for replacement this year. I own more shares than volume today. 

[CalgaryATE]

If you go to around the 22/23 minute mark of the Radius Research interview (Apr. 19, 2021) https://www.youtube.com/watch?v=AUOUcUAbzG0 Dan talks about 352, I believe he said about 12-15 months to start phase 1 (so April, May, June or July 2022 start date).

[MrMugsy]

Now that you say it - I do remember thinking the in-human start date for ATB-352 was strange.  It seemed to have pushed out compared to what was indicated in a Letter to Shareholders - or - the plan in a previous presentation. I am assuming it is related to changes in their strategy - whatever is needed to get to better result from negotiations.

[StockingUp21]

This is exactly my thought. Things does not add up here.   

[GameChangerBet]

Uplisting to Nasdaq, and particularily starting phase lll, these are not necessities for reaching a deal, however, the further along you are in the process, the arguement would be that there is an increase in value, both in terms of real value as well as negotiating power. And yes, pharmas are well aware of Antibe, from my understanding the contacting efforts should be completed by months end. A